Autres langues Camurus AB

Actions

CAMX

SE0007692850

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
676,5 ^SEK	+4,08 %		+6,03 %	+25,74 %

14:00	Transcript : Camurus AB, Q2 2024 Earnings Call, Jul 16, 2024
07:00	Camurus AB (publ) annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Camurus' Interim Report Second Quarter 2024	07:01
Tranche Update on Camurus AB (OM:CAMX)'s Equity Buyback Plan announced on June 28, 2024.	07:00
Camurus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07:00
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients	15/07
Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot in Acromegaly Patients	15/07
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9)	09/07
Change in number of shares and votes in Camurus	28/06
Camurus AB (OM:CAMX) commences an Equity Buyback, under the authorization approved on May 8, 2024.	28/06
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl	25/06
Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study	25/06
Exercise of Camurus' employee stock options program 2021/2024	12/06
Sandberg Development has sold 1.3 million shares in Camurus	11/06
OPINIONI DEGLI ANALISTI DEL GIORNO : Italgas,Telecom Italia, Swisscom, Generali, Centrica, Buzzi, Lonza, Ahold, Sacyr, Richemont...	31/05
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas, Bbva, Sabadell, Cellnex, Fluidra, Lonza, Ahold, Sacyr, Richemont...	31/05
Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2024/2027	30/05
Camurus to present at Jefferies 2024 Healthcare Conference New York	28/05
Camurus' Rare Growth Disorder Drug Accepted for Review in EU	23/05
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly	23/05
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	23/05
Camurus : AGM minutes 2024	13/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Camurus AB

Actions

CAMX

SE0007692850

Autres langues

Filtres